Here are the 10-K annual reports from XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XOMAP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XOMAP filings page.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.